{
    "clinical_study": {
        "@rank": "164770", 
        "acronym": "PATEN", 
        "arm_group": [
            {
                "arm_group_label": "EC-P2", 
                "arm_group_type": "Experimental", 
                "description": "all patients first received 4 cycles of intravenous epirubicin and cyclophosphamide at 3-week intervals and were then  intravenous paclitaxel 2-week intervals for 4 cycles."
            }, 
            {
                "arm_group_label": "EC-P1", 
                "arm_group_type": "Active Comparator", 
                "description": "all patients first received 4 cycles of intravenous epirubicin and cyclophosphamide at 3-week intervals and were then  intravenous paclitaxel 1-week intervals for 12 cycles."
            }
        ], 
        "brief_summary": {
            "textblock": "RATIONALE: Adjuvant chemotherapy has been proven to reduce significantly the risk for\n      relapse and death in women with operable breast cancer.In the North American Inter-Group\n      factorial trial design (CALGB 9741) the concept of dosedense adjuvant chemotherapy was\n      further tested in patients with node-positive breast cancer.Weekly paclitaxel after standard\n      adjuvant chemotherapy with epirubicin and cyclophosphamide improves disease-free and overall\n      survival in women with breast cancer.Investigators asked if dose-dense 2-week intertreatment\n      intervals (supported by the use of granulocyte-colony stimulating factor) were better than\n      the conventional inconvenient weekly intervals."
        }, 
        "brief_title": "Paclitaxol Every 2 Week Versus Paclitaxol Every 1 Week in the Adjuvant Treatment of Breast Cancer", 
        "completion_date": {
            "#text": "December 2020", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Breast Cancer", 
            "Paclitaxel", 
            "Epirubicin", 
            "Cyclophosphamide"
        ], 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age between 18-70 years female operable breast cancer patients\n\n          2. Patients were required to register within 60 days from the final surgical procedure\n             required to adequately treat the  invasive primary tumor.\n\n          3. women who had operable,histologically confirmed adenocarcinoma of the breast with a.\n             histologically involved positive lymph nodes b. or histologic diagnosis for three\n             negative patients; c. or lymph node negative, HER2 positive(if HER2 + +, FISH\n             (fluorescence in situ hybridization method)/CISH tests confirmed HER2 amplification\n             is positive),but unable or intolerant to herceptin combined chemotherapy.\n\n          4. Karnofsky  points greater than or equal to 70.\n\n          5. Postmenopausal women or HCG test results were negative, Women of child-bearing\n             potential willing to use effective contraception during the study.\n\n          6. PATIENT CHARACTERISTICS:\n\n        Hematopoietic:\n\n          -  Neutrophil count at least 1,500/mm^3\n\n          -  Platelet count at least 100,000/mm^3\n\n        Hepatic:\n\n          -  Bilirubin no greater than 1.5 times upper limit of normal\n\n          -  TBIL no greater than 1.5 times upper limit of normal\n\n          -  AKP no greater than 2.5 times upper limit of normal\n\n          -  AST no greater than 2.5 times upper limit of normal\n\n          -  ALT no greater than 2.5 times upper limit of normal\n\n        Renal:\n\n          -  Creatinine no greater than 1.5 times upper limit of normal\n\n        Cardiovascular:\n\n          -  No history of myocardial infarction\n\n          -  No congestive heart failure\n\n          -  No significant ischemic or valvular heart disease\n\n        Other:\n\n          -  No other prior invasive malignancies within the past 5 years except curatively\n             treated basal or squamous cell skin cancer or carcinoma in situ of the cervix\n\n          -  No hypersensitivity to paclitaxel or docetaxel or other similarly formulated drugs\n             (with Cremophor or polysorbate)\n\n        Other protocol-defined inclusion/exclusion criteria may apply.\n\n        Exclusion Criteria:\n\n        -"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "1000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01848197", 
            "org_study_id": "ZJTC0001"
        }, 
        "intervention": {
            "arm_group_label": [
                "EC-P2", 
                "EC-P1"
            ], 
            "intervention_name": "paclitaxel", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Paclitaxel"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 6, 2013", 
        "number_of_arms": "2", 
        "official_title": "An Open, Randomized, Parallel-group, Multicenter Clinical Study to Evaluate Efficacy and Safety of Paclitaxel Every 2 Weeks Compared Weekly in Adjuvant Treatment of Breast Cancer", 
        "other_outcome": [
            {
                "measure": "Explore the relationship between neuropathy and DFS and the related predictive biomarkers (RWDD3 and TECTA gene SNP etc)", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "Explore predictive biomarker of neutropenia;", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }
        ], 
        "overall_official": {
            "affiliation": "Zhejiang Taizhou Hospital", 
            "last_name": "Feilin Cao, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "time from randomization to disease recurrence (including death from recurrence if it was the first manifestation of recurrence), death without recurrence, or contralateral breast cancer.", 
            "measure": "disease-free survival", 
            "safety_issue": "Yes", 
            "time_frame": "3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01848197"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Taizhou Hospital", 
            "investigator_full_name": "Feilin Cao", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "time from randomization to disease recurrence (including death from recurrence if it was the first manifestation of recurrence), death without recurrence, or contralateral breast cancer.", 
                "measure": "disease-free survival", 
                "safety_issue": "Yes", 
                "time_frame": "5 years"
            }, 
            {
                "description": "time from randomization to disease death with/without recurrence breast cancer.", 
                "measure": "overall survival", 
                "safety_issue": "Yes", 
                "time_frame": "5 years"
            }
        ], 
        "source": "Taizhou Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Taizhou Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}